(RTTNews) – We are hardly two weeks into 2021, and shares of Relmada Therapeutics Inc. (RLMD) have gained 22% so far this year.

Relmada is a late-stage biotech company developing drugs to treat diseases of the central nervous system in an entirely new way. The lead drug candidate is REL-1017, a novel NMDA receptor (NMDAR) channel blocker that…

All your Asset management needs with Global Asset Management Seoul Korea Magazine

This post was originally published on this site

Share.

Comments are closed.